• +1-646-491-9876
    • +91-20-67278686

    Search

    Anaphylaxis Pipeline Review H1 2017

    Anaphylaxis Pipeline Review H1 2017

    • Report Code ID: RW0001799284
    • Category Pharmaceuticals
    • No. of Pages 38
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Anaphylaxis - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Anaphylaxis - Pipeline Review, H1 2017, provides an overview of the Anaphylaxis (Immunology) pipeline landscape.

    Anaphylaxis is a severe, potentially life-threatening allergic reaction. Anaphylaxis symptoms include dizziness, nausea, vomiting or diarrhea, feeling of warmth, constriction of the airways and a swollen tongue or throat. Risk factors include personal history of anaphylaxis, allergies or asthma and family history. Treatment includes beta-agonist, antihistamines and cortisone.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Anaphylaxis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Anaphylaxis (Immunology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Anaphylaxis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Anaphylaxis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration and Preclinical stages are 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

    Anaphylaxis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Anaphylaxis (Immunology) .
    - The pipeline guide reviews pipeline therapeutics for Anaphylaxis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Anaphylaxis (Immunology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Anaphylaxis (Immunology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Anaphylaxis (Immunology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Anaphylaxis (Immunology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Anaphylaxis (Immunology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Anaphylaxis - Overview
    Anaphylaxis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Anaphylaxis - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Anaphylaxis - Companies Involved in Therapeutics Development
    Adamis Pharmaceuticals Corp
    MannKind Corp
    Monosol Rx LLC
    Anaphylaxis - Drug Profiles
    epinephrine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    epinephrine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    epinephrine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    epinephrine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ET-523 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Antagonize FcgR1 for Systemic Anaphylaxis, Autoimmune Arthritis, Pulmonary Inflammation and Thrombocytopenia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Antagonize FcgRIIa for Systemic Anaphylaxis, Autoimmune Arthritis, Pulmonary Inflammation and Thrombocytopenia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Anaphylaxis - Dormant Projects
    Anaphylaxis - Product Development Milestones
    Featured News & Press Releases
    Jan 19, 2017: Adamis Announces FDA Acceptance of Resubmission of Its Epinephrine Pre-Filled Syringe NDA
    Jan 10, 2017: MonoSol Rx to Initiate Human Proof-of-Concept Study of Epinephrine Sublingual Soluble Film
    Dec 16, 2016: Adamis Pharmaceuticals Announces New Drug Aplication Resubmission of Its Epinephrine Pre-Filled Syringe Application to the FDA
    Jun 06, 2016: Adamis Receives Complete Response Letter From FDA For Its Epinephrine Pre-Filled Syringe NDA
    Jan 14, 2016: Adamis Pharmaceuticals Announces FDA Acceptance of Resubmission of Its Epinephrine Pre-Filled Syringe NDA
    Dec 07, 2015: Adamis Pharmaceuticals Announces NDA Resubmission of Its Epinephrine Pre-Filled Syringe Application to the FDA
    Aug 06, 2015: Adamis Pharmaceuticals Provides Regulatory Update on Its Epinephrine Pre-Filled Syringe
    Mar 27, 2015: Adamis Pharmaceuticals Receives Complete Response Letter From FDA for Its Epinephrine Pre-Filled Syringe NDA
    Oct 15, 2014: Adamis Pharmaceuticals Announces Key Additions to Medical and Commercial Teams
    Jul 29, 2014: FDA Accepts for Review Adamis' New Drug Application for Its Epinephrine Pre-Filled Syringe
    May 29, 2014: Adamis Submits New Drug Application to FDA for Its Epinephrine Pre-Filled Syringe
    Sep 10, 2013: Novel Nasal Epinephrine Shows Comparable Absorption to EpiPen (R) in a Feasibility Study
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Anaphylaxis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Anaphylaxis - Pipeline by Adamis Pharmaceuticals Corp, H1 2017
    Anaphylaxis - Pipeline by MannKind Corp, H1 2017
    Anaphylaxis - Pipeline by Monosol Rx LLC, H1 2017
    Anaphylaxis - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Anaphylaxis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Adamis Pharmaceuticals Corp
    MannKind Corp
    Monosol Rx LLC

    Request for Sample

    Report Url http://www.reportsweb.com//anaphylaxis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//anaphylaxis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//anaphylaxis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments